Objective:To systematically evaluate the clinical efficacy of Wuling capsules in the treatment of insomnia.Methods:The randomized controlled trial (RCT) literature related to the treatment of insomnia with Wuling capsules was searched by computer through PubMed, EMbase, China National Knowledge Infrastructure (CNKI), China Biology Medicine (CBM), Wanfang, and VIP databases. These RCT literature was searched by using "Wuling capsule and Insomnia" as keywords, and the search time frame was from the establishment of each database to January 2022. The literature was screened and relevant data were collected according to the designed nesting criteria (patients accepted conventional western medicines such as benzodiazepines or new non-benzodiazepines were used as control group, and patients accepted Wuling capsules alone or combined with conventional western medicines were used as study group; the outcome measures included total response rate, total scores of Pittsburgh Sleep Quality Index or Sleep Disorders Rating Scale), and Meta-analysis was performed on the extracted literature data using Revman 5.4 software.Results:A total of 17 pieces of RCT literature met the criteria were finally included, with a total of 1493 patients, including 749 patients into the study group and 744 patients into the control group. The overall efficiency of the study group was significantly higher than that of the control group (relative risk [ RR]=1.270, 95%CI: 1.200-1.340, P<0.05), and total scores of Pittsburgh Sleep Quality Index scale in study group were significantly lower than those in the control group (weighted mean difference [ WMD]=-2.070, 95%CI: -2.610--1.520, P<0.05), and the total scores of Sleep Disorder Rating Scale in study groups were significantly lower than those in the control group ( WMD=-4.180, 95%CI: -4.900--3.450, P<0.05). Conclusion:The efficacy of Wuling capsules alone or combined with conventional western medicines in treating insomnia is better than that of conventional western medicines, and can obviously improve the quality of sleep of patients.

Objective To observe the efficacy,safety and optimum dose of pramipexole in treating patients with essential tremor (ET).Methods Patients in line with diagnostic criteria of essential tremor (ET),collected in our hospital from May 2011 to December 2012,were chosen in our study.Registration and follow-up files were established and a five-week treatment with pramipexole was routinely given to these patients:week 1:0.25 mg/d (0.125 mg bid),week 2:0.375 mg/d (0.125 mg rid); week 3:0.5 mg/d(0.25 mg bid),and week 4:0.75 mg/d (0.25 mg tid); dose adjustment was based on the rating scale for ET of the National Institutes of Health of United States and the subjective feelings of the patients after treatment with pramipexole every week; all patients were required to increase the amount of pramipexole at week 2; if the effect was the same as before in referral at week 3 by increasing the amount of pramipexole,increasing the amount was not needed; otherwise,increasing the amount was continued until the tremor symptoms was no longer worsen.The amount of some patients could be increased to 1.5 mg/d (0.5 mg tid) at week 5.At week 6,the efficacy and dose of all patients were evaluated and recorded to analyzed the treatment efficacy and optimum dose; treatment emergent symptom scale (TESS) was employed to assess the side effects.Results Forty six patients completed the study; symptom relief was noted in 45 patients with a total efficacy rate reaching 97.83％.An obvious statistical difference existed in the differential daily dose of Pramipexole (x2=32.473,P=0.000); an obvious statistical difference existed between the dose of 1.5 mg/d (0.5 mg tid) and others doses (P＜0.05).The most common side effects were hallucination,dizziness and orthostatic hypotension,but disappeared with the drug reduction or withdrawal; no patient gave up treatment resulting from the side effect.Conclusion Pramipexole is highly effective and safe in the treatment of patients with ET; the suitable effective dose is 1.5 mg/d (0.5 mg tid); it can be used as the first-line treatment for ET.

Objective To assess the examinational value of tissue equalization (TE)technique in DR thoracolumbar vertebral body photography. Methods 48 cases were reformed using the conventional DR method in the thoracolumbar vertebral body photography,compared with the TE technique in DR thoracolumbar vertebral body photography. Results The details in different thickness area of body could be revealed clearly in the same image produced by TE technique. The visualization of image details could be obviously improved by using the TE technique. Conclusion It is important to apply the TE technique in DR thoracolumbar vertebral body photography.

[Objective] To investigate the occurrence rate, manifestations and influencing factors of emotional disorder in patients after acute stroke. [Methods] Emotional disorder in 107 cases of acute stroke was assessed by 17-item Hamilton Depression Scales (HAMD), 14-item Hamilton Anxiety Scales (KAMA), Mini-Mental State Examination (MMSE) and Barthel index (BI), and the relationship between emotional disorder and influencing factors were also analyzed. [Results] The occurrence rate of emotional disorder after acute stroke was 41.12% , in which depression was 18.69% , anxiety 9.35% and concurrence of depression and anxiety 13.08% . Emotional disorder usually occurred in the dominant hemisphere of young patients with lower BI after repeated attacks of stroke; its manifestations relieved with the cure of primary diseases. Its dominant syndrome pattern was classified as stagnation of liver-Qi. [ Conclusion ] Emotional disorder, possibly being a stress reaction, is the common complications of acute stroke and usually classified as stagnation of liver-Qi; early effective rehabilitation is the best preventive method for emotional disorder acute stroke.